CompletedNCT00203567
Extended-release carbamazepine for bipolar depression
About this title
Read the official source — NCT00203567Medication studyAges 19–65United StatesBipolarity
Understand this study
Who was this study for?
This study was for people with bipolarity. Listed age limits: 19 years to 65 years. Other eligibility criteria applied.
- Listed locations
- TuscaloosaSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateAugust 2005
- Recruitment status
- Completed
- Enrollment listed in the registry
- 25
- Sponsor
- Tuscaloosa Research & Education Advancement Corporation
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 19 Years to 65 Years
- Official registry ID
- NCT00203567
- Official title
Show the full official title
Carbamazepine Extended-Release for the Treatment of Bipolar Depression
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Tuscaloosa
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Tuscaloosa Research & Education Advancement Corporation.
Did this study involve medication?
Yes. The study involved medication, including carbamazepine ER.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 19 years to 65 years. Other eligibility criteria applied.
